These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20515945)

  • 1. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.
    Olesen UH; Thougaard AV; Jensen PB; Sehested M
    Mol Cancer Ther; 2010 Jun; 9(6):1609-17. PubMed ID: 20515945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.
    Nahimana A; Attinger A; Aubry D; Greaney P; Ireson C; Thougaard AV; Tjørnelund J; Dawson KM; Dupuis M; Duchosal MA
    Blood; 2009 Apr; 113(14):3276-86. PubMed ID: 19196867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.
    Cagnetta A; Caffa I; Acharya C; Soncini D; Acharya P; Adamia S; Pierri I; Bergamaschi M; Garuti A; Fraternali G; Mastracci L; Provenzani A; Zucal C; Damonte G; Salis A; Montecucco F; Patrone F; Ballestrero A; Bruzzone S; Gobbi M; Nencioni A; Cea M
    Clin Cancer Res; 2015 Sep; 21(17):3934-45. PubMed ID: 25964294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
    Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.
    Yang HJ; Yen MC; Lin CC; Lin CM; Chen YL; Weng TY; Huang TT; Wu CL; Lai MD
    Exp Biol Med (Maywood); 2010 Jul; 235(7):869-76. PubMed ID: 20558841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
    Watson M; Roulston A; Bélec L; Billot X; Marcellus R; Bédard D; Bernier C; Branchaud S; Chan H; Dairi K; Gilbert K; Goulet D; Gratton MO; Isakau H; Jang A; Khadir A; Koch E; Lavoie M; Lawless M; Nguyen M; Paquette D; Turcotte E; Berger A; Mitchell M; Shore GC; Beauparlant P
    Mol Cell Biol; 2009 Nov; 29(21):5872-88. PubMed ID: 19703994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
    Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
    Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study.
    Zerp SF; Vens C; Floot B; Verheij M; van Triest B
    Radiother Oncol; 2014 Feb; 110(2):348-54. PubMed ID: 24412016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotinamide phosphoribosyltransferase inhibitor APO866 induces C6 glioblastoma cell death via autophagy.
    Yang P; Zhang L; Shi QJ; Lu YB; Wu M; Wei EQ; Zhang WP
    Pharmazie; 2015 Oct; 70(10):650-5. PubMed ID: 26601421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
    Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
    BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.
    Nahimana A; Aubry D; Breton CS; Majjigapu SR; Sordat B; Vogel P; Duchosal MA
    Leuk Lymphoma; 2014 Sep; 55(9):2141-50. PubMed ID: 24283753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis.
    Evans L; Williams AS; Hayes AJ; Jones SA; Nowell M
    Arthritis Rheum; 2011 Jul; 63(7):1866-77. PubMed ID: 21400478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
    Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
    Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
    Hasmann M; Schemainda I
    Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
    Venkateshaiah SU; Khan S; Ling W; Bam R; Li X; van Rhee F; Usmani S; Barlogie B; Epstein J; Yaccoby S
    Exp Hematol; 2013 Jun; 41(6):547-557.e2. PubMed ID: 23435312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.
    Zoppoli G; Cea M; Soncini D; Fruscione F; Rudner J; Moran E; Caffa I; Bedognetti D; Motta G; Ghio R; Ferrando F; Ballestrero A; Parodi S; Belka C; Patrone F; Bruzzone S; Nencioni A
    Exp Hematol; 2010 Nov; 38(11):979-88. PubMed ID: 20696207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
    Ogino Y; Sato A; Uchiumi F; Tanuma SI
    Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.
    Breton CS; Aubry D; Ginet V; Puyal J; Heulot M; Widmann C; Duchosal MA; Nahimana A
    Biochimie; 2015 Sep; 116():141-53. PubMed ID: 26188110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.